Trade Schrödinger, Inc. - SDGR CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.12
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.022262 %(-$4.45)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02226%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00004 %($0.01)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: 0.00004%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.022262 %
  (-$4.45)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00004 %
  ($0.01)

Key Stats

• Prev. Close: 28.78
• Open: 28.16
• 1-Year Change: 46.44%
• Day's Range: 28.16 - 29.98

Trade Schrödinger, Inc. - SDGR

Schrödinger (SDGR) is a computational platform that facilitates the discovery of molecules for drug development and materials design for biopharmaceutical, academic institutions and government laboratories. 

Founded in 1990, Schrödinger is headquartered in New York. The company has customers and collaborators across more than 70 countries. Its collaborators include Agios Therapeutics, Ajax Therapeutics, Bright Angel Therapeutics, Eli Lilly and Company and Sanofi. 

Schrödinger specialises in oncology, antifungal, fibrosis, inflammatory bowel diseases, metabolic diseases, cardiopulmonary diseases, tuberculosis, neurodegenerative disease and more. 

MALT1 inhibitor is a key regulator of physiological antigen receptor signalling in B cells and T cells and are additive to covalent and non-covalent BTK inhibitors. The company announced US Food and Drug Administration (FDA) clearance of an investigational new drug application for SGR-1505, a MALT1 Inhibitor. 

Schrödinger leverages the software platform to advance its collaborative programmes and its novel therapeutics pipeline includes eight compounds that address unmet medical needs and are currently in the clinical development phase.

Schrödinger, Inc. stock began trading on the NASDAQ in 2020 under the ticker symbol SDGR. 

You can track live SDGR share value and price history at Capital.com.